Clinical Trials
45 trialsBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Novartis
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Comparison of Clomid and Lezra With Lezra for Ovulation Induction in Clomid Resistant PCOS Case
HITEC-Institute of Medical Sciences
PIKASSO-01
Eli Lilly and Company
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Providence Health & Services
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech, Inc.
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Rutgers, The State University of New Jersey
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Massachusetts General Hospital
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
Ono Pharmaceutical Co., Ltd.
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
BeiGene
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
PALVEN
Peter MacCallum Cancer Centre, Australia
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Genentech, Inc.
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
Kyowa Kirin Co., Ltd.
Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol
Egymedicalpedia
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
BeBetter Med Inc
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Novartis
Pharmacokinetics and Hepatic Safety of EGCG
Yale University
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Jonsson Comprehensive Cancer Center
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Celcuity Inc
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Haihe Biopharma Co., Ltd.
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
M.D. Anderson Cancer Center
LeeBLet
Novartis
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Dartmouth-Hitchcock Medical Center
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
AstraZeneca
Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics
Centro Nacional de Investigaciones Oncologicas CARLOS III
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions
West-Ward Pharmaceutical
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions
West-Ward Pharmaceutical
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
Genentech, Inc.
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
National Cancer Institute (NCI)
RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Study to Compare Between Combimed Metformin-letrozole and Ovarian Drilling in Pcos With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome
Zagazig University
Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
OHSU Knight Cancer Institute
Aromatase Inhibitors for Treatment of Uterine Leiomyomas
American University of Beirut Medical Center